跳至主要内容
临床试验/NCT00222976
NCT00222976已完成4 期

Oral vs Rectal Administration of Naproxen for Post-Vaginal Perineal Pain Control: A Randomized Clinical Trial

University of Saskatchewan1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
60
试验地点
1
主要终点
post-vaginal delivery perineal pain scores will be measured using a visual analog scale.

研究概览

简要总结

The primary objective of this study is to determine whether the route of administration of naproxen (either by mouth or rectally) influences post-vaginal delivery perineal pain control.

详细描述

Postpartum perineal pain is common after vaginal delivery. Naproxen suppositories have been shown to be effective at reducing postpartum perineal pain. To date, no studies have investigated the efficacy of oral naproxen for perineal pain control. Currently, rectal naproxen is used postpartum because of an assumption that there is a "local effect" compared to oral administration. However, this effect has never been documented in the literature.

Principles of pharmacology dictate that the least invasive route of drug administration should be used when two or more routes are equally effective. If oral and rectal naproxen are equally efficacious at controlling post-vaginal delivery perineal pain, then current practice would be challenged.

The primary objective of this study is to determine whether the route of administration of naproxen influences post-vaginal delivery perineal pain control. Pain scores will be measured using a visual analog scale. The secondary outcome measures are three-fold: patient preference of route of administration, medication adverse effects, and additional requests for analgesia. The working hypothesis is that there is no difference in pain control between oral and rectal administration and that patients will prefer the oral route.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Potential volunteers who meet all of the following criteria are eligible for this study:
  • Active labor, whether spontaneous or induced
  • Age between 18 and 40 years old
  • Nulliparous
  • Single live intrauterine fetus in cephalic presentation
  • Term gestation (370 weeks to 416 weeks inclusive) as defined by ultrasound or last menstrual period dating
  • Intrapartum epidural labour analgesia
  • Written informed consent

排除标准

  • Potential volunteers meeting one of more of the following criteria may not be enrolled:
  • Medical conditions including:
  • Naproxen, aspirin or other non-steroidal anti-inflammatory drug hypersensitivity
  • Peptic ulcer disease or other inflammatory gastrointestinal disease
  • Renal, hepatic or cardiac disease
  • Coagulopathy
  • Rectal or anal pathology including recent (within 1 month) rectal bleeding
  • Prescribed medications including lithium, furosemide, antihypertensives, anticoagulants, aminoglycosides, hydantoins, or sulfonamides
  • Obstetrical conditions including:
  • Multiple pregnancy
  • Extensive perineal trauma (third or fourth degree laceration)
  • Forceps delivery
  • Cesarean section delivery
  • Paracervical or pudendal nerve blocks
  • Vulval or vaginal hematomas
  • Nulliparous women not requiring intrapartum epidural labour analgesia

研究组 & 干预措施

1

Experimental

A Naproxen PO + placebo PR

干预措施: Naproxen (Drug)

2

Experimental

B Placebo PO + Naproxen PR

干预措施: Naproxen (Drug)

结局指标

主要结局

post-vaginal delivery perineal pain scores will be measured using a visual analog scale.

时间窗: 1 day

次要结局

  • patient preference of route of administration(1 day)
  • medication adverse effects(until completion of study)
  • additional requests for analgesia.(until completion of study)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验